We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
- Authors
Kruis, W; Schreiber, S; Theuer, D; Brandes, J W; Schütz, E; Howaldt, S; Krakamp, B; Hämling, J; Mönnikes, H; Koop, I; Stolte, M; Pallant, D; Ewald, U
- Abstract
Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug. Its efficacy in comparison with standard mesalazine therapy and the optimum dose for maintaining remission of ulcerative colitis are still unclear.
- Publication
Gut, 2001, Vol 49, Issue 6, p783
- ISSN
0017-5749
- Publication type
Journal Article
- DOI
10.1136/gut.49.6.783